Background: Clinicians and patients want to know the benefits and harms of outpatient
treatment options for the Omicron variant of SARS-CoV-2. Purpose: To assess the benefits …

Background: COVID-19 has been linked to the development of many post–COVID-19
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …

This systematic review and meta‐analysis aimed to compare the effectiveness and safety of
azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 …

A clear understanding of real-world uptake of nirmatrelvir–ritonavir for treatment of SARS-
CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness …

This opinion piece emphasies the critical role of translational research in enhancing the
UK's resilience against future pandemics. The COVID-19 pandemic demonstrated the …

Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …

Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …

How do we best use Paxlovid and other covid antivirals? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …